Molecular Partners AG (MOLN) - Total Liabilities

Latest as of September 2025: CHF16.62 Million CHF ≈ $21.01 Million USD

Based on the latest financial reports, Molecular Partners AG (MOLN) has total liabilities worth CHF16.62 Million CHF (≈ $21.01 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MOLN asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Molecular Partners AG - Total Liabilities Trend (2013–2024)

This chart illustrates how Molecular Partners AG's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Molecular Partners AG asset portfolio.

Molecular Partners AG Competitors by Total Liabilities

The table below lists competitors of Molecular Partners AG ranked by their total liabilities.

Company	Country	Total Liabilities
Castles Technology Co Ltd TW:5258	Taiwan	NT$4.96 Billion
Tekna Holding AS OL:TEKNA	Norway	Nkr18.33 Million
Cegedim S.A. PA:CGM	France	€704.39 Million
Avantium Holding BV AS:AVTX	Netherlands	€206.57 Million
KHVATEC Co.Ltd KQ:060720	Korea	₩172.59 Billion
TEMC Co. Ltd. KQ:425040	Korea	₩248.01 Billion
Seoul City Gas KO:017390	Korea	₩437.20 Billion
LVMC Holdings KO:900140	Korea	₩196.53 Billion

Liability Composition Analysis (2013–2024)

This chart breaks down Molecular Partners AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See MOLN net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	9.28	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.17	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.15	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Molecular Partners AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Molecular Partners AG (2013–2024)

The table below shows the annual total liabilities of Molecular Partners AG from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	CHF16.89 Million ≈ $21.35 Million	-22.95%
2023-12-31	CHF21.92 Million ≈ $27.72 Million	-19.08%
2022-12-31	CHF27.09 Million ≈ $34.25 Million	-58.56%
2021-12-31	CHF65.38 Million ≈ $82.66 Million	-18.61%
2020-12-31	CHF80.33 Million ≈ $101.55 Million	+58.13%
2019-12-31	CHF50.80 Million ≈ $64.22 Million	-19.95%
2018-12-31	CHF63.45 Million ≈ $80.22 Million	+129.12%
2017-12-31	CHF27.69 Million ≈ $35.01 Million	-42.67%
2016-12-31	CHF48.30 Million ≈ $61.07 Million	-28.55%
2015-12-31	CHF67.60 Million ≈ $85.47 Million	+48.44%
2014-12-31	CHF45.54 Million ≈ $57.57 Million	-26.31%
2013-12-31	CHF61.80 Million ≈ $78.13 Million	--

About Molecular Partners AG

SW:MOLN Switzerland Biotechnology

Market Cap

$163.60 Million

CHF129.40 Million CHF

Market Cap Rank

#17854 Global

#181 in Switzerland

Share Price

CHF3.46

Change (1 day)

+6.46%

52-Week Range

CHF2.75 - CHF3.95

All Time High

CHF38.40